Clinical Trials Logo

Adynamic Bone Disease clinical trials

View clinical trials related to Adynamic Bone Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT04522622 Recruiting - Clinical trials for Chronic Kidney Diseases

Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease

Start date: December 15, 2021
Phase: Phase 4
Study type: Interventional

This study is a 1:1 randomized controlled trial with an intervention for 18 months and a follow up period of 12 months. The purpose of the study is to assess the safety and efficacy of recombinant human parathyroid hormone for treatment of adynamic bone disorder in patients with chronic kidney disease.

NCT ID: NCT03063190 Withdrawn - Clinical trials for Vitamin D Deficiency

Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease

RLS
Start date: March 31, 2022
Phase: Phase 4
Study type: Interventional

Restless leg syndrome (RLS) is sleep disorder characterized by an unpleasant feeling in the lower limbs, which can be accompanied by paresthesias, and need for urgent movement of the legs. Its diagnosis is clinical, based on an International Committee of the Study of RLS (International Restless Legs Syndrome Study) questionnaire. Its prevalence is about 5-15% in the general population, being twice as frequent in women and with a tendency to increase incidence with aging. In the chronic kidney disease (CKD) population, mainly in patients on dialysis, the prevalence increases by up to 70%. Vitamin D deficiency is associated with RLS and active vitamin D supplementation seems to improve RLS and severity. It is seems, studies on the role of vitamin D supplementation in CKD population are missing. The clinical-scientific hypothesis of this study is that replacement of vitamin D (cholecalciferol) will improve the symptoms of RLS. As parathyroidectomy can relieve RLS, the aim of researchers is to randomize patients with CKD on dialysis to receive cholecalciferol or placebo in 2 distinct groups: secondary hyperparathyroidism and adynamic bone disease.